Stockscreener 앱 받기
0.93
3.91%
0.035
시간 외 거래:
.95
0.02
+2.15%
전일 마감가:
$0.895
열려 있는:
$0.895
하루 거래량:
71,185
Relative Volume:
0.67
시가총액:
$50.58M
수익:
$31.09M
순이익/손실:
$-28.51M
주가수익비율:
-1.55
EPS:
-0.6
순현금흐름:
$-22.59M
1주 성능:
+0.00%
1개월 성능:
-14.68%
6개월 성능:
-3.89%
1년 성능:
-18.42%
1일 변동 폭
$0.895
$0.9714
1주일 범위
$0.895
$1.04
52주 변동 폭
$0.70
$2.15
Cytosorbents Corp Stock (CTSO) Company Profile
명칭
Cytosorbents Corp
전화
973-329-8885
주소
305 COLLEGE ROAD EAST, PRINCETON, NJ
CTSO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CTSO | 0.93 | 50.58M | 31.09M | -28.51M | -22.59M | -0.60 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-07 | 개시 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2020-09-17 | 개시 | Jefferies | Buy |
| 2020-09-01 | 개시 | SVB Leerink | Outperform |
| 2017-08-08 | 재확인 | Maxim Group | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-05-24 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 재확인 | MLV & Co | Buy |
| 2015-04-01 | 재확인 | MLV & Co | Buy |
| 2015-03-05 | 개시 | MLV & Co | Buy |
| 2015-02-25 | 개시 | WBB Securities | Speculative Buy |
| 2015-01-27 | 재확인 | H.C. Wainwright | Buy |
모두보기
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
Granahan Investment Management Reduces Stake in CytoSorbents Cor - GuruFocus.com
FY2024 EPS Estimates for Cytosorbents Decreased by Analyst - Defense World
FY2024 EPS Estimate for Cytosorbents Decreased by Analyst - MarketBeat
Cytosorbents Corporation (NASDAQ:CTSO) Q3 2024 Earnings Call Transcript - Insider Monkey
CytoSorbents And Converge Biotech Announce Strategic - GlobeNewswire
CytoSorbents Expands Into India Through Strategic Converge Biotech Partnership | CTSO Stock News - StockTitan
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - MarketBeat
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
CytoSorbents Corp (CTSO) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Improved ... - Yahoo Finance
Cytosorbents Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CytoSorbents Corporation’s Q3 2024 Financial Highlights - TipRanks
CytoSorbents: Q3 Earnings Snapshot - CT Insider
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results - StockTitan
CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ah - GuruFocus.com
CytoSorbents Corp (CTSO) Q3 2024: Everything You Need to Know Ahead of Earnings - Yahoo Finance
CytoSorbents (STU:HQE1) 3-Year EPS without NRI Growth Rate : -38.10% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 3-Year EBITDA Growth Rate : -37.70% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 3-Year FCF Growth Rate : -39.10% (As of Jun. 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) 5-Day RSI : 14.64 (As of Nov. 05, 2024) - GuruFocus.com
CytoSorbents (STU:HQE1) Operating Income : €-23.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification - StockTitan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Cytosorbents (CTSO) to Release Earnings on Thursday - MarketBeat
Cytosorbents (NASDAQ:CTSO) and Caliber Imaging & Diagnostics (OTCMKTS:LCDX) Critical Comparison - Defense World
Analyst Scoreboard: 5 Ratings For CytoSorbents - Benzinga
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts - Benzinga
FDA begins review of CytoSorbents' bleeding reduction device - Investing.com
FDA begins review of CytoSorbents' bleeding reduction device By Investing.com - Investing.com UK
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review - StockTitan
CytoSorbents (STU:HQE1) Forward Dividend Yield % : 0.00% (As of Nov. 05, 2024) - GuruFocus.com
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results - StockTitan
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - MarketBeat
Cytosorbents Co. (NASDAQ:CTSO) Short Interest Down 5.7% in September - MarketBeat
CytoSorbents Corp (CTSO) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance
CytoSorbents maintains Buy rating from B.Riley with no change in target price - Investing.com
Cytosorbents announces $20 million "at the market" equity offering - Investing.com
Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits - Quantisnow
DrugSorb-ATR seeks FDA priority review for surgery bleeding - Investing.com
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update - The Manila Times
Cytosorbents (NASDAQ:CTSO) Research Coverage Started at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) shareholders have endured a 81% loss from investing in the stock three years ago - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - MarketBeat
Stocks of Cytosorbents Corp (CTSO) are poised to climb above their peers - SETE News
Technical analysis of Cytosorbents Corp (CTSO) stock chart patterns - US Post News
Cytosorbents (NASDAQ:CTSO) Share Price Passes Above Two Hundred Day Moving Average of $0.94 - MarketBeat
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference - Yahoo Finance
Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com - Defense World
Cytosorbents Corp (CTSO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.43%
자본화:
|
볼륨(24시간):